Immunocore Holdings plc (Nasdaq: IMCR) announced on September 14, 2026, that its registrational Phase 3 clinical trial, TEBE-AM, has achieved its target enrollment of 540 patients. The trial is evaluating KIMMTRAK (tebentafusp) in combination with pembrolizumab and as monotherapy for patients with advanced melanoma.
The TEBE-AM trial is a global, randomized study designed for HLA-A*02:01-positive patients with advanced melanoma who have progressed following prior therapy, including anti-PD1 treatment and ipilimumab. The study is divided into three arms: tebentafusp as monotherapy, tebentafusp in combination with an anti-PD-1, and a control arm. The primary endpoint of the trial is overall survival.
Patients enrolled in the trial will continue to be followed for the planned overall survival analysis. The company expects to share topline data as early as the end of 2026. Immunocore believes tebentafusp has the potential to address a significant unmet need for up to 4,000 HLA-A*02:01-positive patients with previously treated advanced melanoma in the United States and Europe.
